Navigation Links
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009

RANCHO CORDOVA, Calif., Jan. 29 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2008, on Wednesday, February 4, 2009.

Company's Conference Call and Webcast

Management will host a conference call Wednesday, February 4, 2009 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal second quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1- 412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. Matthew Plavan, Chief Executive Officer will host the call to discuss the second quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit:


A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

     ThermoGenesis Corp.
     Web site:
     Contact: Investor Relations
     1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Presentation at Rodman & Renshaw Conference
2. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
3. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
6. ThermoGenesis Names Tiffany Olson to Board of Directors
7. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
8. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
11. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
Post Your Comments:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):